 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||||||||| Nurdati (prolgolimab/nurulimab) / Biocad
New P3 trial: NEO-MIMAJOR: A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma (clinicaltrials.gov) - Mar 2, 2023
P3, N=410, Recruiting, Sponsor: Biocad
- |||||||||| Nurdati (prolgolimab/nurulimab) / Biocad
New P3 trial, Monotherapy, Metastases: OCTAVA: A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma (clinicaltrials.gov) - Feb 17, 2023
P3, N=270, Recruiting, Sponsor: Biocad
- || Nurdati (prolgolimab/nurulimab) / Biocad
Enrollment closed, Trial completion date, Trial primary completion date, Monotherapy, Metastases: OBERTON: Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Feb 10, 2023
P2, N=117, Active, not recruiting, Sponsor: Biocad
Unknown status --> Active, not recruiting | Trial completion date: Nov 2021 --> Dec 2023 | Trial primary completion date: Aug 2021 --> Jul 2023
- ||| Nurdati (prolgolimab/nurulimab) / Biocad
Enrollment open, Trial completion date, Monotherapy, Metastases: OBERTON: Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Jul 26, 2020
P2, N=112, Recruiting, Sponsor: Biocad
Unknown status --> Active, not recruiting | Trial completion date: Nov 2021 --> Dec 2023 | Trial primary completion date: Aug 2021 --> Jul 2023 Not yet recruiting --> Recruiting | Trial completion date: Sep 2022 --> Nov 2021
- |||| Nurdati (prolgolimab/nurulimab) / Biocad
New P2 trial, Monotherapy, Metastases: OBERTON: Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Apr 11, 2019
P2, N=136, Not yet recruiting, Sponsor: Biocad